Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

INTRODUCTION: Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with myelodysplastic syndrome (MDS) in clinical trials. We studied the association of timing of ESA initiation, agent (epoetin alfa, darbepoetin) and number of weeks of ES...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leuk Res
Main Authors: Duong, Vu H., Baer, Maria R., Hendrick, Franklin, Weiss, Sheila R., Sato, Masayo, Zeidan, Amer M., Gore, Steven D., Davidoff, Amy J.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4441842/
https://ncbi.nlm.nih.gov/pubmed/25869077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.03.013
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker